Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$53.85
-2.34 (-4.16%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-32.6M · quality 44.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.8B
P/E
51.3x
↑EV/EBITDA
32.3x
↑ROE
4.9%
↑Gross Margin
34.8%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.4%
FCF CAGR
—
FCF margin
-22.1%
FCF / Net income
-1.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $602.3M · net income $114.7M · FCF $-133.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $602.3M | $602.3M | $451.9M | $388.8M | $447.5M |
| Net Income | $114.7M | $114.7M | $134.1M | $99.0M | $129.4M |
| EBITDA | $167.9M | $167.9M | $174.7M | $126.7M | $161.1M |
| EPS | 1.07 | 1.07 | 1.24 | 1.07 | 1.60 |
| Gross Margin | 34.8% | 34.8% | 40.3% | 38.6% | 43.3% |
| Operating Margin | 19.4% | 19.4% | 24.7% | 22.8% | 32.4% |
| Net Margin | 19.0% | 19.0% | 29.7% | 25.5% | 28.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 5.41 | 5.41 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-133.0M | $-133.0M | $18.6M | $-32.6M | $57.3M |
| Returns | |||||
| ROE | 4.9% | 4.9% | 5.9% | 4.5% | 26.8% |
| Valuation | |||||
| P/E | 51.29 | 51.29 | 30.99 | 54.85 | — |
| EV/EBITDA | 32.26 | 32.26 | 21.73 | 29.13 | — |
| P/B | 2.45 | 2.45 | 1.83 | 2.45 | — |
| Growth & Yield | |||||
| Revenue Growth | 33.3% | 33.3% | 16.2% | -13.1% | — |
| EPS Growth | -13.7% | -13.7% | 15.8% | -33.1% | — |
| Dividend Yield | 1.2% | 1.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
64.7%
EPS terminal req.
$4.78
Spread vs growth
-78.4%
5Y implied EPS CAGR
40.1%
EPS terminal req.
$5.78
Spread vs growth
-53.8%
10Y implied EPS CAGR
24.2%
EPS terminal req.
$9.31
Spread vs growth
-37.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+2.7%
Start / end P/E
42.8x → 50.4x
EPS bridge
1.24 → 1.07
Residual
-2.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.